1
Enquiry period
with 23.09.2024 17:36
to 02.10.2024 18:00
8 days left
2
Bidding period
with 02.10.2024 18:00
to 09.10.2024 18:30
3
Auction
10.10.2024 15:00
4
Evaluation

5
Contract

Status Enquiry period
Estimated value without VAT 3 532 692,80 MDL
Period of clarifications: 23 Sep 2024, 17:36 - 2 Oct 2024, 18:00
Submission of proposals: 2 Oct 2024, 18:00 - 9 Oct 2024, 18:30

Supplier technical support:

(+373) 79999801

Subscribe

În scopul atribuirii contractelor subsecvente ca urmare a acordului-cadru nr.ocds-b3wdp1-MD-1717573954027 din 15.08.2024 încheiat prin procedura de achiziție publică nr.ocds-b3wdp1-MD-1717573954027 din 08.07.2024 privind “ Achiziţionarea medicamentelor pentru tratamentul Artritei juvenile în scopul realizării Programului National „Combatarea maladiilor rare” pentru anul 2025-2027”

Information about customer
Fiscal code/IDNO
Address
MD-2005, MOLDOVA, mun.Chişinău, locality, mun. Chișinău MD-2005, bd. Grigore Vieru, 22/2
Web site
---
The contact person
Full name
Macari Doina
Contact phone
+37322222490
Purchase data
Date created
23 Sep 2024, 17:19
Date modified
23 Sep 2024, 17:36
Achizitii.md ID
21282226
CPV
33600000-6 - Produse farmaceutice
Type of procedure
Open tender
Award criteria
The lowest price
Funding sources
List of lots
Lot nr. 1 - Tocilizumab 80 mg/4 ml
Budget: 311469.02 MDL
Active
Lot nr. 2 - Golimumab 45 mg/0.45ml
Budget: 1557733.25 MDL
Active
Lot nr. 3 - Golimumab 50 mg/0.5ml
Budget: 1663490.53 MDL
Active
Documents of the procurement procedure
Invitatie pentru reofertare.signed
Bidding Documents
Invitatie pentru reofertare.signed
23.09.24 17:36
contract subsecvent
Bidding Documents
contract subsecvent
23.09.24 17:36
Propunerea financiara
Technical Specifications
Propunerea financiara
23.09.24 17:36
Propunerea tehnică
Technical Specifications
Propunerea tehnică
23.09.24 17:36
AcordCadru_NR_ocds...57027.semnat.semnat (1).signed
Bidding Documents
AcordCadru_NR_ocds...57027.semnat.semnat (1).signed
23.09.24 17:36
Question's name
Question
Only authorized platform users may ask questions during the clarification period.